-+ 0.00%
-+ 0.00%
-+ 0.00%

Goldman Sachs Maintains Neutral on HUTCHMED (China), Lowers Price Target to $14

Benzinga·07/23/2026 16:15:45
語音播報
Goldman Sachs analyst Paul Choi maintains HUTCHMED (China) (NASDAQ:HCM) with a Neutral and lowers the price target from $16 to $14.